HEALTHglobal
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer
Single source
Updated 2 hours ago
First seen March 16, 2026 23:10:16Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Company shares spiked more than 60% after the therapy surpassed Wall Street benchmarks in Phase 1 testing against late-line colorectal tumors.